Román-Fernández I, González-González Y, Da Cuña-Carrera I

Language: Spanish
References: 17
Page: 16-25
PDF size: 435.24 Kb.

ABSTRACT

Introduction: Life expectancy after diagnosis Amyotrophic lateral sclerosis (ALS) is 2 to 5 years, and approximately 20% of patients live more than 5 years. Only one drug, Riluzol, has been approved for the treatment of ALS, which extends the patient’s lifespan by a few months, therefore, there is a need to develop more effective therapies for this disorder. Stem cell therapy is a promising potential treatment option for ALS, for this reason the objective of this review is to investigate the results of treatment with stem cells in patients with ALS and thus open new paths to its effectiveness.
Material and methods: During the months of March and April 2017, a search was made of the Medline, Web of Science and Scopus databases.
Results: 13 valid studies have been selected for the review and we found various surgical procedures were used to administer stem cells. Among the study variables, the most important measures are bulbar function, motor function, respiratory function, muscle strength, respiratory volume and flow and spasticity.
Conclusions: Beneficial results were obtained, since there were significant improvements in the measured variables and there was no apparent progression of the disease related to the surgical procedure. It can be concluded that treatment with stem cells in patients with ALS is safe and viable, however, studies should continue to be carried out that provide greater reliability in terms of the sample and effects obtained.

REFERENCES

1. Ratti E, Berry JD. Amyotrophic Lateral Sclerosis 1 and Many Diseases. In: Lehner T, Miller BL, State MW, editors. Genomics, circuits and pathways in clinical Neuropsychiatry. London: Academic Press; 2016, 685-712.

2. Donsante A, Urquia LN, Boulis NM. Stem cells for Amyotrophic Lateral Sclerosis. In: Tuszynski MH, editor. Translational Neuroscience 2016; 227-258.

3. Mao Z, Zhang S, Chen H. Stem cell therapy for amyotrophic lateral sclerosis. BioMed Central. 2015; 4(11).

4. Prabhakar S, Marwaha N, Lal V, Sharma R.R, Rajan R, Khandelwal N. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: A pilot study. Neurology India 2012; 60(5).

5. Mazzini L, Gelati M, Profico D.C, Sgaravizzi G, Pensi M.P, Muzi G, et al. Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med 2015; 13(17).

6. Riley J, Glass J.D, Feldman E.L, Polak M, Bordeau J, Federici T, et al. Intraspinal Stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery 2014; 74(1): 77-87.

7. Glass J.D, Boulis N.M, Johe K, Rutkove S.B, Federici T, Polak M, et al. Lumbar intraspinal injection of neural stem cells in patients with Amyotrophic Lateral Sclerosis: results of a phase I trial in 12 patients. Stem Cells 2012; 30(6): 1144-1151.

8. García-Santos J.M, Inuggi A, Gómez-Espuch J, Vázquez C, Iniesta F, Blanquer M, et al. Spinal cord infusion of stem cells in amyotrophic lateral sclerosis: magnetic resonance spectroscopy shows metabolite improvement in the precentral gyrus. Stem Cells 2016; 18(6): 785-96.

9. Rushkevich Y.N, Kosmacheva S.M, Zabrodets G.V, Ignatenko S.I, Goncharova N.V, Severin I.N, et al. The use of autologous mesenchymal stem cells for cell therapy of patients with Amyotrophic Lateral Sclerosis in Belarus. Exp Biol Med. 2015; 159(4): 576-581.

10. Mazzini L, Mareschi K, Ferrero I, Miglioretti M, Stecco A, Servo S, et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Elsevier 2012; 14(1): 56-60.

11. Martínez H.R, Molina-López J.F, González-Garza M.T, Moreno-Cuevas J.E, Caro-Osorio E, Gil-Valadez A, et al. Stem Cell Transplantation in Amyotrophic Lateral Sclerosis Patients: methodological approach, safety, and feasibility. Cell Transplantation, 21(9), 1899-907. https://doi.org/10.3727/096368911X582769

12. Ki-Wook O, Chanil M, Young K.H, Sung-il O, Jinseok P, Ho L.J, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in Amyotrophic Lateral Sclerosis. Stem Cells Transl Med. 2015; 4(6): 590-597.

13. Ruiz-López F.J, Guardiola J, Izura V, Gómez-Espuch J, Iniesta F, Blanquer M, et al. Breathing pattern in a phase I clinical trial of intraspinal injection of autologous bone marrow mononuclear cells in patients with amyotrophic lateral sclerosis. Elsevier. 2016; 221: 54-58.

14. Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy Y.S, Kassis I, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with Amyotrophic Lateral Sclerosis: results of phase 1/2 and 2ª clinical trials. JAMA Neurol. 2016; 73(3): 337-344.

15. Riley J, Federici T, Polak M, Kelly C, Glass J, Raore B, et al. Intraspinal Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery 2012; 71(2): 405-416.

16. Feldman E.L, Boulis N.M, Hur J, Johe K, Rutkove S.B, Federici T, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: Phase 1 trial outcomes. Annals of Neurology. 2014; 75(3): 363-373.

17. Leigh N, Sreedharan J, Wijesekera L. Motor Neuron Disease: Amyotrophic Lateral Sclerosis. In: Pfaff D.W, Volkow N.D, editors. Neuroscience in the 21st Century. 2ª ed. New York. Springer; 2016. p. 3799-3841.